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Particular Association of Clinical and Genetic Features
With Autoimmunity to Citrullinated -Enolase in
Rheumatoid Arthritis
Ariana Montes,1 Rebeca Dieguez-Gonzalez,1 Eva Perez-Pampin,1 Manuel Calaza,1
Antonio Mera-Varela,2 Juan J. Gomez-Reino,2 and Antonio Gonzalez1
Objective. To confirm that the presence of anti–
citrullinated -enolase peptide 1 (anti–CEP-1) anti-
bodies identifies a subgroup of patients with rheuma-
toid arthritis (RA).
Methods. DNA and serum samples were obtained
from 451 patients with RA and 279 healthy control
subjects, all of whom were of Spanish ancestry. Anti-
bodies to cyclic citrullinated peptide (CCP) and CEP-1
were measured by enzyme-linked immunosorbent assay.
HLA–DRB1 and the R620W single-nucleotide poly-
morphism of PTPN22 were genotyped.
Results. Anti–CEP-1 and anti-CCP antibodies
were observed in 26.8% and 71.2% of the patients with
RA, respectively. Most of the patients (86.6%) with
anti–CEP-1 antibodies also had anti-CCP antibodies.
Erosive arthritis, rheumatoid factor (RF) positivity, and
the presence of the HLA shared epitope (especially the
DRB1*04 alleles) were disproportionately associated
with the group of patients with both antibodies. In
addition, evidence of a significant interaction between
the shared epitope and the risk allele of PTPN22 was
observed only in these patients. In contrast, the associ-
ation with these clinical and genetic features was weaker
in patients with anti-CCP antibodies but lacking anti–
CEP-1 antibodies. These results were obtained in pa-
tients in whom the prevalence of RA risk factors differed
from that in other previously studied patients.
Conclusion. We observed that autoimmunity
against citrullinated -enolase may identify a subset of
patients with a higher frequency of joint erosions and
RF positivity. In addition, we confirmed the dispropor-
tionately large effect of the susceptibility alleles of
HLA–DRB1 and their interaction with PTPN22 in this
subset of patients. These results extend, confirm, and
generalize the evidence supporting the specificity of the
anti–CEP-1 antibody–positive subgroup of patients with
RA among anti-CCP antibody–positive patients with RA.
One of the most fruitful findings in recent rheu-
matoid arthritis (RA) research has been the identi-
fication of anti–cyclic citrullinated peptide (anti-CCP)
antibodies (1,2). They are very specific to RA, and they
appear in 60–70% of patients. They are useful for
clinical diagnostics and have been included in the new
criteria for RA in patients with early arthritis (3). In
addition, anti-CCP antibody status is important from
both the clinical and pathogenic sides of RA (4).
Antibody-positive patients have a more erosive dis-
ease (5,6) that progresses even during treatment with
disease-modifying antirheumatic drugs (7–10). Such pa-
tients have a worse response to tumor necrosis factor
blockers (11) but a better response to B cell depletion
(12). In addition, many genetic susceptibility factors are
restricted to the anti-CCP antibody–positive subset of
RA patients, with no or weak effects in antibody-
negative patients. Clear examples of such factors include
HLA (13,14), PTPN22 (15), and tumor necrosis factor
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receptorassociated factor 1/C5 (16). In contrast, no
genetic factors have been shown conclusively to be
specific to anti-CCP antibody–negative patients (17),
and only a few factors, such as STAT-4 (18), seem to be
shared by the 2 subpopulations of patients with RA. Also
of interest is the specific association of smoking with the
anti-CCP antibody–positive subset of RA patients (19–
21), although this association has not been observed in
all patient cohorts (22–24).
All of these data and other experimental results
have led to a very attractive hypothesis for the etiology
of anti-CCP antibody–positive RA that combines ge-
netic predisposition and citrullination of proteins in the
lungs of smokers (4,19,25). This combination of genetic
and environmental risk factors leads to the development
of autoantibodies against the citrullinated proteins,
which could precede overt joint inflammation by several
years. There are still some areas of uncertainty in this
model. For example, it is unknown whether or not all
citrullinated proteins recognized by antibodies in the
plasma of patients with RA are equally relevant to
pathogenesis.
A recent study showed strong support for a
particular role of citrullinated -enolase (26). This pro-
tein is a widely expressed glycolytic enzyme that is
up-regulated in RA synovium beginning early in the
disease course (27,28). Antibodies against its citrulli-
nated form are specific to RA (28–30). Many of them
recognize the immunodominant citrullinated -enolase
peptide 1 (CEP-1) (29). The particular role of these
antibodies in RA pathogenesis was supported by their
stronger association with HLA, PTPN22, and smoking
than was observed with other anti-CCP antibody–
positive patients (26). Interestingly, -enolase shows
strong similarity and antibody cross-reactivity with eno-
lase from Porphyromonas gingivalis, which is involved in
periodontitis and perhaps in RA etiology (29). In addi-
tion, CEP-1 will be an excellent target for the design of
very specific treatments (31).
In this study, we confirmed the particular associ-
ation of the presence of anti–CEP-1 antibodies in pa-
tients with RA and the risk alleles of HLA–DRB1 and
PTPN22. In addition, we identified a particular associa-
tion with erosive arthritis and the presence of rheuma-
toid factor (RF).
PATIENTS AND METHODS
Acquisition of DNA and serum samples. DNA and
serum samples from 451 patients with RA and 279 healthy
adult (age 55 years) control subjects of Spanish ancestry were
obtained at a single hospital. Patients with RA were classified
according to the 1987 American College of Rheumatology
criteria (32). The Ethical Committee for Clinical Research of
Galicia approved this study, and all participants gave their
written informed consent. The smoking history of the patients
with RA was recorded as either never smoker or smoker (past
or current).
Serologic assessment. The anti-CCP antibody status of
the patients was determined using the EDIA Anti-CCP ELISA
(Euro-Diagnostica). The cutoff level was set at 5 units/ml,
according to the manufacturer’s instructions. Anti–CEP-1
antibodies were assayed following the previously described
enzyme-linked immunosorbent assay protocol (26). The CEP-1
peptide (CKIHA-X-EIFDS-X-GNPTVEC) (29) was synthe-
sized at Abcam. A standard curve based on serial dilutions
from pooled antibody-positive sera was used to measure
antibody titers in arbitrary units (AUs). The cutoff for positiv-
ity was set at the mean plus 3 SD of the AU values from 173
of the healthy control subjects.
HLA–DRB1 and PTPN22 genotyping. HLA–DRB1
alleles were determined by a sequencing-based typing method,
using the AlleleSEQR HLA–DRB1 Typing Kit (Abbott Diag-
nostics), which includes a single polymerase chain reaction
(PCR) amplification for all alleles of the second exon of DRB1
and bidirectional sequencing. Alleles were assigned using
Assign-SBT version 3.2.7 software (Abbott Diagnostics). Am-
biguous samples were additionally sequenced with group-
specific primers (AlleleSEQR HLA–DRB1 GSSP; Abbott).
The PTPN22 rs2476601 single-nucleotide polymorphism
(SNP) was genotyped with a TaqMan SNP genotyping assay
(Applied Biosystems). A Chromo4 real-time PCR system (MJ
Research) was used to run this assay.
Statistical analysis. Dichotomous variables were ana-
lyzed as 2  2 contingency tables. Genotypes were analyzed by
logistic regression according to an additive model with codes 0
for AA, 1 for Aa, and 2 for aa genotypes. For a comparison of
the effects between HLA–DRB1*01 and HLA–DRB1*04, sub-
jects with no shared epitope (SE) were used as the common
reference group. These analyses were performed using Statis-
tica version 7.0 (StatSoft). Interaction analysis was carried out
in R, implementing the formulas for departure from additivity
developed by Hosmer and Lemeshow (33). The group of
antibody-negative patients was used as reference, and the
presence of either of the genetic factors, DRB1 and PTPN22,
was considered only as carrier or no-carrier. A logistic regres-
sion model incorporating a multiplicative interaction term was
also tested.
RESULTS
Stratification of patients with RA according to
anti–CEP-1 and anti-CCP status. Serum samples from
451 Spanish patients with RA were analyzed for the
presence of anti-CCP and anti–CEP-1 antibodies (the
clinical characteristics of the patients are available from
the corresponding author). Anti-CCP antibodies were
present in 71.2% of the patients, and anti–CEP-1 anti-
bodies were present in 26.8% of the patients. None of
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the 173 healthy control subjects was positive for either
of the antibodies. Figure 1 shows the stratification of
patients with RA into 4 subsets. Only 16 patients were
both anti-CCP antibody negative and anti–CEP-1 anti-
body positive, and they were not analyzed further. The
other 3 subsets of patients were designated as anti-CCP/
anti–CEP-1, anti-CCP/anti–CEP-1, and anti-CCP/
anti–CEP-1. Although 86.6% of the patients with anti–
CEP-1 antibodies also had anti-CCP antibodies, these
patients represented fewer than one-third of all anti-
CCP antibody–positive patients. This distribution is
different from that previously described in other RA
patient cohorts (Table 1) (26), with the exception of the
UK Norfolk Arthritis Register collection, which showed
a similar fraction of anti–CEP-1 antibody–positive pa-
tients relative to either the whole set of patients with RA
or anti-CCP antibody–positive patients.
Titers of anti-CCP antibodies were not higher in
the anti-CCP/anti–CEP-1 subgroup of patients com-
pared with the anti-CCP/anti–CEP-1 subgroup (P 
0.6 by Mann-Whitney U test). In addition, titers of
anti–CEP-1 and anti-CCP antibodies did not correlate
(rs  0.03 in the anti-CCP/anti–CEP-1 subgroup).
This lack of correlation means that particular associa-
tions with anti–CEP-1 antibodies cannot be ascribed to
higher titers of anti-CCP antibodies.
Higher prevalence of joint erosion and RF in the
anti-CCP/anti–CEP-1 subgroup of patients with RA.
Very important differences were observed between the
anti-CCP/anti–CEP-1 subgroup and both the anti-
CCP/anti–CEP-1 and anti-CCP/anti–CEP-1 sub-
groups in the prevalence of joint erosion (44.4%, 74.5%,
and 87.1%, respectively) (Figure 2). There were also
differences between the anti-CCP/anti–CEP-1 and
anti-CCP/anti–CEP-1 subgroups, with a greater
prevalence of erosion in the group with both antibodies
(P  0.01). Also, the prevalence of RF was much higher
in patients with anti-CCP antibodies compared with that
in patients in the anti-CCP/anti–CEP-1 subgroup
(78.6% versus 16.3%). Within the group of anti-CCP
antibody–positive patients, the prevalence of RF posi-
tivity was higher in the anti-CCP/anti–CEP-1 sub-
group than in the anti-CCP/anti–CEP-1 (85.3% ver-
sus 74.1%) (Figure 2). The prevalence of sicca syndrome
Figure 1. Stratification of the patients with rheumatoid arthritis ac-
cording to their anti–cyclic citrullinated peptide (anti-CCP) and anti–
citrullinated -enolase peptide 1 (anti–CEP-1) antibody status. The
anti-CCP/anti–CEP-1 subgroup comprised 112 patients, the anti-
CCP/anti–CEP-1 subgroup comprised 213 patients, the anti-CCP/
anti–CEP-1 subgroup comprised 103 patients, and the anti-CCP/
anti–CEP-1 subgroup comprised 16 patients. For 7 patients, no
information on anti-CCP status was available.
Table 1. Characteristics of the RA patients in the current study compared with those in 3 previously described RA patient cohorts*
Frequency, % P, versus current study
Current study EIRA NR NOAR EIRA NR NOAR
Anti–CEP-1 26.8 43 41 27 4.9  109 8.2  105 NS
Anti-CCP 71.2 60 92 51 4.8  105 1.4  1011 3.1  107
Anti–CEP-1/anti-CCP 23.2 38 40 23 3.8  108 1.2  106 NS
SE carrier† 53.7 79.1 86.3 64.5 9.3  1021 3.8  1019 0.01
HLA–DRB1*01 30.6 15.3 9.4 21.2 1.8  1010 3.7  1011 0.013
HLA–DRB1*04 27.6 62.1 60.6 34.0 3.5  1031 2.4  1018 0.10
620W carrier† 26.1 30.3 – – 0.12 – –
Ever smoker† 19.2 69.9 – – 4.7  1062 – –
* The 3 cohorts previously described by Mahdi et al (26) are as follows: 1,000 patients from the Epidemiological Investigation of Rheumatoid
Arthritis (EIRA), a Swedish population-based case–control study; 279 patients from the UK National Repository (NR); and 218 patients from the
UK Norfolk Arthritis Register (NOAR). NS  not significant; SE  shared epitope.
† Data on the percentages of anti–cyclic citrullinated peptide antibody–negative/anti–citrullinated -enolase peptide 1–positive (anti-CCP/anti–
CEP-1) patients with these features in the cohorts described by Mahdi et al were not available; therefore, the data were calculated excluding this
group.
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showed a trend in the same direction, but the differences
were not significant (data not shown). These results are
the first showing a particular association of autoimmu-
nity against -enolase with clinical features of RA.
Preferential association of the HLA–DRB1 SE
with the anti-CCP/anti–CEP-1 subgroup of patients.
The HLA–DRB1 SE was more frequent in patients with
RA than in control subjects (53.7% versus 29.0%; P 
1.2  109), and this association was allele dose depen-
dent; that is, the association was stronger in SE homozy-
gotes than in SE heterozygotes. The difference was
much more marked between control subjects and pa-
tients with anti-CCP antibodies (58.9%; P  3.35 
1012) than between control subjects and anti-CCP
antibody–negative patients (39.3%; P  0.06). It was
even more exaggerated between control subjects and
patients positive for both antibodies (Figure 3); almost
70% of patients in the anti-CCP/anti–CEP-1 sub-
group were carriers of the SE (69.9%; P  9.0  1014
versus control). The most interesting comparison was
between this subgroup of anti-CCP/anti–CEP-1 pa-
tients and the subgroup of anti-CCP/anti–CEP-1
patients (SE frequency 53.5%; P  0.0009). The sig-
nificant excess of association of the SE with patients
who were positive for both antibodies confirmed the
already described particular association of autoimmu-
nity against -enolase with the HLA–DRB1 risk alleles
(26). In addition, the correlation between the number of
SE alleles and anti–CEP-1 antibody titers was confirmed
(rs  0.13, P  0.006).
Previous studies have shown that the association
between the different SE alleles and anti–CEP-1
antibody–positive RA is not uniform (26,30,34). We also
observed a stronger association of anti–CEP-1 anti-
bodies with HLA–DRB1*04 alleles than with HLA–
DRB1*01 alleles (additional information is available
from the corresponding author). Our confirmatory re-
sults were obtained in spite of the lower percentage of
RA patients bearing SE alleles, the higher contribution
of the HLA–DRB1*01 alleles, and the lower percentage
of HLA—DRB1*04 alleles in our Spanish patients than
in patients from Sweden or the UK in the study by
Mahdi et al (26) (Table 1).
Synergism between the 2 main RA genetic risk
factors in the anti-CCP/anti–CEP-1 subgroup of
patients. The PTPN22 620W allele is the second major
genetic risk factor for RA. In our patients, it was
associated with RA, but only in those with anti-CCP
antibodies (16.6% of control subjects were carriers,
compared with 18.0% of patients in the anti-CCP/
anti–CEP-1 subgroup; P not significant). The 620W
allele was more common in patients who were positive
for both antibodies (34.0% of patients in the anti-CCP/
anti–CEP-1 subgroup were carriers, compared with
Figure 3. Preferential association of the shared epitope (SE) in the
anti-CCP/anti–CEP-1 subgroup of patients with rheumatoid arthri-
tis. The percentages of subjects carrying the specified number of SE
alleles are shown, as well as the P values for all pairwise comparisons
between each group of subjects, as obtained in an additive logistic
regression model. CRL  control (see Figure 1 for other definitions).
Figure 2. Relationship between erosive arthritis and rheumatoid fac-
tor (RF) positivity in rheumatoid arthritis, patients in the anti-CCP/
anti–CEP-1 subgroup. The prevalence of these clinical features in
each subgroup is shown, as well as the P values for all pairwise
comparisons between subgroups. The minor subgroups comprised 12
anti-CCP/anti–CEP-1 patients without erosions, and 14 anti-
CCP/anti–CEP-1 patients without RF. See Figure 1 for other
definitions.
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26.4% of patients in the anti-CCP/anti–CEP-1 sub-
group), but the difference between the anti-CCP/anti–
CEP-1 and the anti-CCP/anti–CEP-1 subgroups
was not significant (P  0.2) (additional information is
available from the corresponding author).
Analysis of interactions between the SE and the
620W allele of PTPN22 showed a significant deviation
from additivity only in the subset of patients positive for
both antibodies. In this group, the deviation from addi-
tivity is reflected by the difference between the percent-
age of patients who had the SE but did not carry the
620W risk allele (63.2%), and the percentage of patients
who carried both risk alleles (82.9%) (Figure 4). The
attributable proportion (AP) of disease due to this
interaction was 0.59 (95% confidence interval 0.19–0.98;
P  0.002). In contrast, the AP in the anti-CCP/anti–
CEP-1 subgroup was not significantly different from 0.
No significant multiplicative interaction was observed
using a logistic regression model. These interaction
results confirm previous findings by Mahdi et al (26).
Impact of smoking. The prevalence of smoking in
our patients was low (18.7%), especially in women (8.2%
versus 53.7% in men). These data are similar to those
reported in our area for the general population in the
patients’ age range (35–37). We did not have informa-
tion about smoking for the control subjects, and a direct
comparison was therefore not possible. Smoking was
equally prevalent in our patients with RA indepen-
dently of the antibody status (22.6% in the anti-CCP/
anti–CEP-1 subgroup, 18.5% in the anti-CCP/anti–
CEP-1 subgroup, and 17.0% in the anti-CCP/anti–
CEP-1 subgroup). The small number of smokers
prevented meaningful comparisons, but a trend toward a
positive interaction with the SE in anti-CCP antibody–
positive patients was detected (AP  0.43; P  0.07).
DISCUSSION
Our analysis contributes to defining the role of
autoimmunity against citrullinated -enolase in RA.
Our specific contribution includes the finding of new
preferential associations with joint erosion and RF
positivity. These associations need to be replicated,
but they suggest that this type of autoimmunity is able
to differentiate a particular subset among anti-CCP
antibody–positive patients. In addition, we replicated the
particular association of anti–CEP-1 antibodies with the
SE and the 620W allele of PTPN22 but highlighted that
smoking is a dispensable factor. Our results add gener-
ality to the results reported by Mahdi et al (26) because
of the important differences between Spanish patients
with RA and Northern European patients with RA in
terms of the prevalence of RA risk factors (38–40).
It has previously been demonstrated that patients
with anti–CEP-1 antibodies show a stronger association
with RA susceptibility factors compared with patients
who have anti-CCP reactivity but lack anti–CEP-1 anti-
bodies (26). We have added the first evidence of a
predominant association with erosive arthritis and RF
positivity. The stronger association with these 2 features
could suggest that autoimmunity against different citrul-
linated proteins determines not only different levels of
disease susceptibility but also different disease pheno-
types. An alternative suggestion is that these clinical
associations could be secondary to a stronger relation-
ship between anti–CEP-1 antibodies and other factors,
such as DRB1*04 alleles, which themselves are more
strongly associated with erosion and RF positivity. Ad-
ditional studies are required to confirm the new prefer-
ential associations and to examine the possible effect of
subclassification by the anti–CEP-1 antibodies in other
facets of the phenotype and progression of RA.
Our results confirm the particular association of
Figure 4. Representation of the interaction between shared epitope
(SE) alleles and the 620W allele of PTPN22 in subgroups of patients
with rheumatoid arthritis (RA) and control (CRL) subjects. Although
the number of SE alleles is shown, the analyses were performed using
carrier status. Significant evidence of deviation from additivity in the
interaction between the 2 genetic factors was observed only in RA
patients in the anti-CCP/anti–CEP-1 subgroup (P  0.002). The
minor subgroup comprised 6 patients in the anti-CCP/anti–CEP-1
subgroup who were carriers of 620W but were not carriers of the SE.
See Figure 1 for other definitions.
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the SE in patients positive for both anti-CCP and
anti–CEP-1 antibodies (26). This independent confir-
mation was obtained in a population in whom the
HLA–DRB1 allele frequencies were different from
those previously reported (38,39), with fewer SE and
DRB1*04 alleles and more DRB1*01 alleles. Neverthe-
less, the association was stronger with the DRB1*04
alleles than with the DRB1*01 alleles, as described in
other populations (26,30). There was also a significant
interaction between the SE and the risk allele of
PTPN22, and this was observed only in patients in the
anti-CCP/anti–CEP-1 subgroup. This interaction
was previously demonstrated in the Epidemiological
Investigation of RA cohort of patients, and it likely
represents biologic interaction between the 2 suscepti-
bility factors (26,41). Possible molecular mechanisms
include recognition of CEP-1 in the context of the SE
alleles of HLA–DR by autoreactive T cells, with a lower
threshold for activation due to the risk allele of PTPN22.
Replication of the SE and PTPN22 associations
with anti–CEP-1 reactivity in a population with a much
lower exposure to tobacco than in most previous studies
is of relevance. It is also notable because no association
was detected between smoking and anti-CCP antibody–
positive status in our patients. This lack of association
has already been reported for some patient collections
(22–24) and shows that the genetic associations with
anti-CCP antibody–positive RA are not completely de-
pendent on smoking. This was already noticeable in
studies showing significant association between the SE
and nonsmoker anti-CCP antibody–positive patients
(22,23,26,41), but the dispensability of smoking was
more evident in our patients. In addition, our results
highlight that a fraction of nonsmoker patients with RA
have anti-CCP antibodies. Disease-triggering factors
that could be involved in these patients include air
pollution and subclinical lung inflammation (22,42) or
inflammation in other tissues such as joint inflammation
triggered by trauma or infection (28,42–44) and peri-
odontitis (45). All of these stimuli are known to increase
protein citrullination. In addition, periodontitis can con-
tribute by molecular mimicry between P gingivalis, the
major agent of periodontitis, and human -enolases
(29,46). Any of these alternative triggering factors could
have been at play in our anti-CCP antibody–positive
patients.
In summary, our results confirm the particular
role of autoimmunity against citrullinated -enolase in
RA by showing that patients with antibodies against its
immunodominant peptide are particularly associated
with erosive arthritis, RF positivity, and the presence of
the SE. They also show a specific interaction between
the SE and the PTPN22 risk allele. These results extend
and confirm previous findings and give them more
generality in populations of European ancestry with
differences in the prevalence of RA risk factors. How-
ever, these results do not exclude the possibility that
antibodies to other citrullinated antigens could also have
particular association with RA features, as has been
shown by the association of SE alleles with antibodies
against a citrullinated vimentin peptide but not with
antibodies against a citrullinated fibrinogen peptide (47).
Research in autoimmunity against specific citrullinated
autoantigens to establish their relative participation in
the spectrum of RA features and genetic associations is
warranted.
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